中国全科医学
中國全科醫學
중국전과의학
CHINESE GENERAL PRACTICE
2014年
14期
1684-1687
,共4页
多囊肾,常染色体显性%纤维化%发病机制
多囊腎,常染色體顯性%纖維化%髮病機製
다낭신,상염색체현성%섬유화%발병궤제
Polycystic kidney,autosomal dominant%Fibrosis%Pathogenesis
多囊肾病是常见的遗传性肾脏疾病,按遗传方式可分为常染色体显性多囊肾病和常染色体隐性多囊肾病。最常见的多囊肾病是常染色体显性多囊肾病,本文分析的多囊肾病特指常染色体显性多囊肾病。对于多囊肾病,囊肿的生长和肾功能丧失均与进展性纤维化有关。肾脏纤维化是各种肾病进展至终末期肾病的重要机制,增加了终末期肾病的发生率,但目前其潜在的发生机制尚未明确。在多囊肾病中,肾脏纤维化的机制包括转化生长因子-β表达上调、间质胶原蛋白表达增加、上皮间质转化及纤溶酶原激活物抑制剂表达增多等。鉴于肾脏纤维化在多囊肾病中的重要作用,阻止或减缓肾脏纤维化能减缓多囊肾病的进展;而有效的抗纤维化治疗依赖于对多囊肾病中肾脏纤维化确切发病机制的了解。本文旨在讨论多囊肾病的进展与肾脏纤维化的关系。
多囊腎病是常見的遺傳性腎髒疾病,按遺傳方式可分為常染色體顯性多囊腎病和常染色體隱性多囊腎病。最常見的多囊腎病是常染色體顯性多囊腎病,本文分析的多囊腎病特指常染色體顯性多囊腎病。對于多囊腎病,囊腫的生長和腎功能喪失均與進展性纖維化有關。腎髒纖維化是各種腎病進展至終末期腎病的重要機製,增加瞭終末期腎病的髮生率,但目前其潛在的髮生機製尚未明確。在多囊腎病中,腎髒纖維化的機製包括轉化生長因子-β錶達上調、間質膠原蛋白錶達增加、上皮間質轉化及纖溶酶原激活物抑製劑錶達增多等。鑒于腎髒纖維化在多囊腎病中的重要作用,阻止或減緩腎髒纖維化能減緩多囊腎病的進展;而有效的抗纖維化治療依賴于對多囊腎病中腎髒纖維化確切髮病機製的瞭解。本文旨在討論多囊腎病的進展與腎髒纖維化的關繫。
다낭신병시상견적유전성신장질병,안유전방식가분위상염색체현성다낭신병화상염색체은성다낭신병。최상견적다낭신병시상염색체현성다낭신병,본문분석적다낭신병특지상염색체현성다낭신병。대우다낭신병,낭종적생장화신공능상실균여진전성섬유화유관。신장섬유화시각충신병진전지종말기신병적중요궤제,증가료종말기신병적발생솔,단목전기잠재적발생궤제상미명학。재다낭신병중,신장섬유화적궤제포괄전화생장인자-β표체상조、간질효원단백표체증가、상피간질전화급섬용매원격활물억제제표체증다등。감우신장섬유화재다낭신병중적중요작용,조지혹감완신장섬유화능감완다낭신병적진전;이유효적항섬유화치료의뢰우대다낭신병중신장섬유화학절발병궤제적료해。본문지재토론다낭신병적진전여신장섬유화적관계。
Polycystic kidney disease( PKD),a common hereditary kidney disease,can be divided,according to mode of inheritance,into autosomal dominant and autosmal recessive,and autosomal dominant PKD is the commonest,which will be analyzed specifically in this paper. For PKD,renal cyst growth and renal functional incapacitation is associated with pro-gressive fibrosis. Renal fibrosis,an important mechanism of progression-to-end-stage kidney disease( KD),leads to inci-dence of end-stage KD,the mechanism of which remains unknown. In PKD,the mechanisms of renal fibrosis include increas-ing expressions of transforming growth factor-β,interstitial collagen protein,epithelial-mesenchymal transition and plasmino-gen activator inhibitor and so on. Given the important role of renal fibrosis in PKD,preventing or slowing renal fibrosis can retard PKD progression. Effective anti-fibrosis therapy depends on the understanding of renal fibrosis mechanism. This paper is aimed to discuss the relationship PKD progression to renal fibrosis.